Long-Term Open-Label Solifenacin Treatment Associated with Persistence with Therapy in Patients with Overactive Bladder Syndrome
- 31 March 2005
- journal article
- clinical trial
- Published by Elsevier in European Urology
- Vol. 47 (3) , 376-384
- https://doi.org/10.1016/j.eururo.2004.11.004
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF THE ONCE DAILY ANTIMUSCARINIC AGENT SOLIFENACIN SUCCINATE IN PATIENTS WITH OVERACTIVE BLADDERJournal of Urology, 2004
- Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladderBJU International, 2004
- 508 New antimuscarinic agent, solifenacin succinate, reduces urgency episodes in overactive bladder: An analysis of over 3000 patientsEuropean Urology Supplements, 2004
- Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instabilityWorld Journal of Urology, 2003
- Twelve-Month Treatment of Overactive BladderDrugs & Aging, 2001
- Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinenceUrology, 1999
- ONCE DAILY CONTROLLED VERSUS IMMEDIATE RELEASE OXYBUTYNIN CHLORIDE FOR URGE URINARY INCONTINENCEJournal of Urology, 1999
- The patient with an overactive bladder—Symptoms and quality-of-life issuesUrology, 1997
- A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder complianceBJOG: An International Journal of Obstetrics and Gynaecology, 1997
- OxybutyninDrugs & Aging, 1995